Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Total Liabilities (2016 - 2026)

Amphastar Pharmaceuticals has reported Total Liabilities over the past 13 years, most recently at $840.5 million for Q4 2025.

  • For Q4 2025, Total Liabilities fell 0.55% year-over-year to $840.5 million; the TTM value through Dec 2025 reached $840.5 million, down 0.55%, while the annual FY2025 figure was $840.5 million, 0.55% down from the prior year.
  • Total Liabilities for Q4 2025 was $840.5 million at Amphastar Pharmaceuticals, down from $889.5 million in the prior quarter.
  • Over five years, Total Liabilities peaked at $949.5 million in Q3 2023 and troughed at $194.8 million in Q1 2021.
  • A 5-year average of $569.0 million and a median of $783.6 million in 2023 define the central range for Total Liabilities.
  • Biggest five-year swings in Total Liabilities: skyrocketed 328.61% in 2023 and later decreased 13.9% in 2024.
  • Year by year, Total Liabilities stood at $226.0 million in 2021, then dropped by 5.61% to $213.3 million in 2022, then skyrocketed by 309.46% to $873.5 million in 2023, then decreased by 3.24% to $845.2 million in 2024, then decreased by 0.55% to $840.5 million in 2025.
  • Business Quant data shows Total Liabilities for AMPH at $840.5 million in Q4 2025, $889.5 million in Q3 2025, and $857.9 million in Q2 2025.